Orthostatic hypotension during vincristine therapy.
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects; D000328:Adult; D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy; D004837:Epinephrine / Q000652:urine; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D009206:Myocardium / Q000032:analysis; D009362:Neoplasm Metastasis; D009638:Norepinephrine / Q000032:analysis / Q000652:urine; D051381:Rats; D013565:Sympatholytics / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D013565:Sympatholytics; D014750:Vincristine; D009638:Norepinephrine; D004837:Epinephrine